Retatrutide is an innovative triple hormone receptor agonist targeting GIP GLP-1 and glucagon receptors currently generating significant clinical interest across the pharmaceutical landscape for its remarkable weight management potential Clinical trials are ongoing worldwide and UK healthcare professionals are closely monitoring its development as a potential next-generation therapeutic option for…